ESR1 and breast carcinoma: This is particularly evident for late-stage breast cancer, of which 15% are classified as triple negative breast cancer (TNBC), defined as tumours that lack oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression [2].